Actively Recruiting
A Cohort Establishment Study of Total Management of Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer
Led by Sichuan Cancer Hospital and Research Institute · Updated on 2024-06-20
500
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
This research aims to establish a cohort to study the comprehensive management of ovarian cancer, including fallopian tube cancer and primary peritoneal cancer. It focuses on evaluating the effects of surgery, chemotherapy, and maintenance therapies on patient prognosis and quality of life. The study also investigates postoperative recovery, complications, adverse reactions, and analyzes factors influencing outcomes in these cancers. Participants will not receive any intervention as this is an observational study. Researchers will monitor patients undergoing standard treatments including surgery, chemotherapy, and targeted maintenance therapies such as PARPi. The study explores the safety and effectiveness of these treatments in real-world clinical settings without altering patient care. During the study, participants will be followed up to assess survival outcomes such as progression-free survival and overall survival about six months after study completion. Researchers will also track adverse reactions and monitor recovery and complications after treatments. The total participation period varies, with follow-ups focusing on long-term prognosis and safety.
CONDITIONS
Brief Title
A Cohort Establishment Study of Total Management of Ovarian Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients diagnosed with ovarian cancer, including fallopian tube cancer and primary peritoneal cancer, intended to be treated at the study hospital
- Ability to cooperate with follow-up visits after treatment
You will not qualify if you...
- Patients with other malignant tumors or a history of other malignant tumors
- Presence of cognitive impairment affecting participation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to approximately 6 months after treatment completion
Participants who undergo routine care for ovarian cancer are observed to study prognosis, recovery, adverse reactions, and treatment outcomes.
Visits scheduled according to routine clinical follow-up
Trial Site Locations
Total: 1 location
1
Sichuan Cancer Hospital
Chengdu, China
Actively Recruiting
Research Team
D
Dengfeng Wang, Learned scholar
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here